title: A new era for the systemic therapy of neuroendocrine tumors.
abstract: Carcinoids and pancreatic neuroendocrine tumors are becoming increasingly common, with the majority of patients presenting with either lymph node involvement or metastatic disease. An improved understanding of the molecular mechanisms involved in these tumors has implicated several pathways that have led to new therapeutic approaches. In this manuscript, we describe the biology of neuroendocrine tumors and approaches to systemic therapy. We review early data regarding the use of cytotoxics and several recent studies employing more targeted approaches that promise to change the standard of care. Specifically, phase III studies indicate that pharmacologic inhibition of the vascular endothelial growth factor pathway with sunitinib, and of the mammalian target of rapamycin pathway with everolimus, appears to have altered the natural history of these diseases. These successes set the stage for further advances in the management of patients with neuroendocrine tumors.
authors.affiliation: University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: Eads
authors.forename: Neal J
authors.initials: NJ
authors.lastname: Meropol
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005770:Gastrointestinal Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D006728:Hormones / Q000097:blood; D006801:Humans; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000235:genetics / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D006728:Hormones